NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC products using ultra-gentle, high-water-content hydrogels, has appointed Kip Crecca to its Scientific Advisory Board. Crecca brings over 20 years of medical device sales and management experience to the role. He currently serves as VP of North America Sales at MicroSurgical Technology and is on the Board of Directors at Ocular Science.
NEXGEL's CEO, Adam Levy, expressed enthusiasm about Crecca's appointment, highlighting his extensive knowledge and experience as a top medical device sales professional. Levy believes Crecca will be invaluable to the company's advancement of medical device and healthcare programs, contributing to growth initiatives and improving patient care globally with NEXGEL's hydrogels.
Crecca stated his excitement to join the Scientific Advisory Board and collaborate with the team to support the development of new therapies using NEXGEL's hydrogel technology.
NEXGEL (NASDAQ: NXGL), un fornitore di prodotti medicali e OTC che utilizza idrogeli ultra-delicati ad alta concentrazione d'acqua, ha nominato Kip Crecca nel suo Comitato Consultivo Scientifico. Crecca porta con sé oltre 20 anni di esperienza nelle vendite e nella gestione di dispositivi medici in questo ruolo. Attualmente ricopre la carica di VP delle Vendite per il Nord America presso MicroSurgical Technology ed è membro del Consiglio di Amministrazione di Ocular Science.
Il CEO di NEXGEL, Adam Levy, ha espresso entusiasmo per la nomina di Crecca, evidenziando la sua vasta conoscenza ed esperienza come professionista di vendita di dispositivi medici di alto livello. Levy crede che Crecca sarà inestimabile per l'avanzamento dei programmi di dispositivi medici e assistenza sanitaria dell'azienda, contribuendo alle iniziative di crescita e migliorando la cura dei pazienti a livello globale con gli idrogeli di NEXGEL.
Crecca ha dichiarato il suo entusiasmo per l'ingresso nel Comitato Consultivo Scientifico e per la possibilità di collaborare con il team per supportare lo sviluppo di nuove terapie utilizzando la tecnologia degli idrogeli di NEXGEL.
NEXGEL (NASDAQ: NXGL), un proveedor de productos médicos y OTC que utiliza hidrogeles ultra-suaves de alta contenido de agua, ha nombrado a Kip Crecca en su Consejo Asesor Científico. Crecca aporta más de 20 años de experiencia en ventas y gestión de dispositivos médicos a este cargo. Actualmente es VP de Ventas en Norteamérica en MicroSurgical Technology y forma parte de la Junta Directiva de Ocular Science.
El CEO de NEXGEL, Adam Levy, expresó su entusiasmo por el nombramiento de Crecca, destacando su amplio conocimiento y experiencia como un destacado profesional de ventas de dispositivos médicos. Levy cree que Crecca será invaluable para el avance de los programas de dispositivos médicos y atención sanitaria de la compañía, contribuyendo a las iniciativas de crecimiento y mejorando la atención al paciente a nivel global con los hidrogeles de NEXGEL.
Crecca mencionó su emoción por unirse al Consejo Asesor Científico y colaborar con el equipo para apoyar el desarrollo de nuevas terapias utilizando la tecnología de hidrogeles de NEXGEL.
NEXGEL (NASDAQ: NXGL)은 초부드럽고 수분 함량이 높은 하이드로겔을 사용하는 의료 및 OTC 제품 제공업체로, Kip Crecca를 과학 자문 위원회에 임명했습니다. Crecca는 이 분야에서 20년 이상의 의료 기기 판매 및 관리 경험을 가지고 있습니다. 현재 MicroSurgical Technology의 북미 판매 부사장을 맡고 있으며, Ocular Science의 이사회에도 있습니다.
NEXGEL의 CEO인 Adam Levy는 Crecca의 임명에 대한 기대감을 표명하며, 그가 우수한 의료 기기 판매 전문가로서 가지는 풍부한 지식과 경험을 강조했습니다. Levy는 Crecca가 회사의 의료 기기 및 헬스케어 프로그램 발전에 없어서는 안될 존재가 될 것이며, NEXGEL의 하이드로겔을 통해 전 세계적으로 환자 관리 개선 및 성장 이니셔티브에 기여할 것이라고 믿고 있습니다.
Crecca는 과학 자문 위원회에 합류하게 되어 기쁘며, NEXGEL의 하이드로겔 기술을 사용한 새로운 치료법 개발을 지원하기 위해 팀과 협력할 것에 대한 기대를 표현했습니다.
NEXGEL (NASDAQ: NXGL), un fournisseur de produits médicaux et OTC utilisant des hydrogels ultra-doux à haute teneur en eau, a nommé Kip Crecca à son Comité Consultatif Scientifique. Crecca apporte plus de 20 ans d'expérience en vente et gestion d'appareils médicaux à ce poste. Il occupe actuellement le poste de VP des Ventes en Amérique du Nord chez MicroSurgical Technology et est membre du Conseil d'Administration d'Ocular Science.
Le CEO de NEXGEL, Adam Levy, a exprimé son enthousiasme quant à la nomination de Crecca, soulignant sa vaste connaissance et expérience en tant que professionnel de la vente d'appareils médicaux de premier plan. Levy pense que Crecca sera inestimable pour l'avancement des programmes de dispositifs médicaux et de soins de santé de l'entreprise, contribuant aux initiatives de croissance et améliorant les soins aux patients à l'échelle mondiale avec les hydrogels de NEXGEL.
Crecca a déclaré son enthousiasme à rejoindre le Comité Consultatif Scientifique et à collaborer avec l'équipe pour soutenir le développement de nouvelles thérapies utilisant la technologie des hydrogels de NEXGEL.
NEXGEL (NASDAQ: NXGL), ein Anbieter von medizinischen und OTC-Produkten, der ultra-sanfte, wasserreiche Hydrogele verwendet, hat Kip Crecca in seinen Wissenschaftlichen Beirat berufen. Crecca bringt über 20 Jahre Erfahrungen im Verkauf und Management von Medizinprodukten in diese Rolle ein. Derzeit ist er VP für Nordamerika-Vertrieb bei MicroSurgical Technology und sitzt im Vorstand von Ocular Science.
Der CEO von NEXGEL, Adam Levy, äußerte sich begeistert über Creccas Ernennung und betonte dabei dessen umfangreiche Kenntnisse und Erfahrungen als führender Vertriebsprofi im Bereich Medizinprodukte. Levy glaubt, dass Crecca für den Fortschritt der medizinischen Geräte- und Gesundheitsprogramme des Unternehmens von unschätzbarem Wert sein wird, da er zu Wachstumsinitiativen beiträgt und die Patientenversorgung weltweit mit NEXGELs Hydrogel verbessert.
Crecca erklärte seine Freude darüber, dem Wissenschaftlichen Beirat beizutreten und mit dem Team zusammenzuarbeiten, um die Entwicklung neuer Therapien mit der Hydrogel-Technologie von NEXGEL zu unterstützen.
- Appointment of experienced medical device sales professional to Scientific Advisory Board
- Potential for advancement in medical device and healthcare programs
- Possible contribution to growth initiatives and global patient care improvement
- None.
LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board.
“We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional,” said Adam Levy, NEXGEL’s CEO. “Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of entrepreneurial individuals with complementary skills and a shared, innovative outlook to drive growth initiatives and continue to better help patients with our hydrogels around the world.”
Mr. Crecca commented, “I am excited to join NEXGEL’s Scientific Advisory Board and collaborate with a talented group of individuals to support the development of new therapies leveraging the Company’s ultra-gentle, high-water-content hydrogels.”
Mr. Crecca brings over two decades of medical device sales and management experience. He currently serves as the VP of North America Sales at MicroSurgical Technology, a leader in the development of advanced surgical instruments and solutions, as well as sitting on the Board of Directors at Ocular Science, a biotech company focused on cost-effective, innovative eye care products. Prior to his current roles, Mr. Crecca served in various sales leadership positions at companies including STAAR Surgical, Abbott Medical Optics, Stryker Endoscopy, and more.
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2022, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
NEXGEL@KCSA.Com
FAQ
Who did NEXGEL (NXGL) appoint to its Scientific Advisory Board?
What is Kip Crecca's background and experience relevant to NEXGEL (NXGL)?
How does NEXGEL (NXGL) expect Kip Crecca to contribute to the company?
What products does NEXGEL (NXGL) specialize in?
